PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 73.50
Bid: 67.00
Ask: 80.00
Change: 3.50 (5.00%)
Spread: 13.00 (19.403%)
Open: 70.00
High: 73.50
Low: 65.00
Prev. Close: 70.00
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First server sale of TexRAD in Canada

12 Jun 2015 07:00

RNS Number : 9742P
Feedback PLC
12 June 2015
 

12 June 2015

 

Feedback plc

("Feedback" or the "Group")

 

First server sale of TexRAD in Canada

 

Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce its first server sale for research purposes in Canada of the Group's TexRAD texture analysis software. The software will be installed in the Department of Diagnostic Radiology at the McGill University Health Centre's ("MUHC") Montreal General Hospital site.

 

The MUHC is one of the leading academic health centres in North America. It was founded in 1997 through the merger of five hospitals including the Montreal General Hospital which was established in 1819 and was one of the world's first teaching hospitals.

 

Professor Benoit Gallix, Chairman, Department of Diagnostic Radiology (McGill University Director, MUHC) commented, "We are very excited with the prospect of evaluating the TexRAD imaging research software platform at our institution as a potential imaging risk-stratification tool. TexRAD will form part of a research study of breast cancer patients who have had digital mammography imaging examinations. The MUHC database has approximately 20,000 digital mammograms with clinical follow-up acquired over a period of 15 to 20 years. This comprehensive research study could help to provide an evidence base for the potential application of TexRAD in breast cancer patient management"

Dr. Balaji Ganeshan, Chief Scientist and New Business Officer at the Group's subsidiaries TexRAD Ltd and Cambridge Computed Imaging Ltd, commented, "We are delighted to receive this first server order in Canada, particularly from the very prestigious MUHC, Montreal, Quebec and we are honoured to be working with Professor Benoit Gallix and his team. Breast cancer is the most common cancer in the UK with around 55,000 people (predominantly women) diagnosed with the disease every year. Research and development into non-invasive imaging based risk-stratification tools such as TexRAD research software could potentially lead to TexRAD's use as a supplementary tool in digital mammography to achieve better patient management and improved overall outcomes in the future."

 

 

For further information contact:

 

Feedback plc

Tel: 01954 718072

Simon Barrell / Trevor Brown / Tom Charlton

Sanlam Securities UK (Nominated Adviser and Joint Broker)

Simon Clements / Virginia Bull

Tel: 020 7628 2200

Peterhouse Corporate Finance Ltd (Joint Broker)

Tel: 020 7469 0936

Lucy Williams / Duncan Vasey

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKKFFAESEFF
Date   Source Headline
2nd Nov 20217:00 amRNSFinal Results
19th Oct 20217:00 amRNSPilot Scheme with Sussex Integrated Care System
11th Oct 20217:00 amRNSMOU with Quest Teleradiology
29th Sep 20217:00 amRNSFeedback Joins NHS AI Procurement Framework
23rd Sep 20217:00 amRNSOfficial Launch of Bleepa Box
14th Sep 20217:00 amRNSMemorandum of Understanding with Qure.ai
9th Sep 20217:00 amRNSLaunch of CareLocker to enhance Bleepa technology
25th Aug 20217:00 amRNSChange of Adviser
3rd Aug 20217:00 amRNSDigital Health article highlights Bleepa potential
16th Jul 20217:00 amRNSBleepa agreement with CVS Equine Division
5th Jul 202110:17 amRNSHolding(s) in Company
30th Jun 20213:30 pmRNSBoard Update
29th Jun 20217:00 amRNSUK Medical Device Certification for Bleepa
10th Jun 20217:00 amRNSBleepa available on Apple App Store & Google Play
8th Jun 20217:00 amRNSYear End Trading Update
6th May 20217:00 amRNSExecutive Appointment
24th Mar 20217:00 amRNSRoyal Berkshire NHS Foundation Trust Contract
23rd Feb 20217:00 amRNSHalf-year Report
19th Jan 20217:00 amRNSBleepa builds on robust data management security
4th Dec 20207:00 amRNSBleepa to join DIT’s first virtual event to India
10th Nov 20209:06 amRNSSelected for Digitalhealth.London 2020 Programme
6th Nov 20203:03 pmRNSResult of Annual General Meeting - Amendment
6th Nov 20201:50 pmRNSHolding(s) in Company
5th Nov 20201:23 pmRNSResult of AGM
5th Nov 20207:01 amRNSBleepa selected for WISH 2020 Innovation Awards
5th Nov 20207:00 amRNSAGM Statement
28th Oct 20203:10 pmRNSDirector/PDMR Shareholding
20th Oct 20207:00 amRNSBleepa adds 3D Imaging with Axial3D Partnership
13th Oct 20207:00 amRNSFinal Results
26th Aug 20201:34 pmRNSHolding(s) in Company
7th Aug 20207:00 amRNSDirector/PDMR Shareholding
5th Aug 20204:36 pmRNSPrice Monitoring Extension
31st Jul 20205:00 pmRNSTotal Voting Rights
30th Jul 20203:48 pmRNSBleepa appointed to major NHSx framework
29th Jul 20202:06 pmRNSSecond Price Monitoring Extn
29th Jul 20202:00 pmRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSAppointment of Non-Executive Director
10th Jul 20207:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 202011:01 amRNSHolding(s) in Company
6th Jul 202010:36 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 202012:46 pmRNSResult of Open Offer and General Meeting
25th Jun 202011:59 amRNSDirector/PDMR Shareholding
15th Jun 20207:00 amRNSPlacing, Open Offer and Notice of GM
1st Jun 20207:00 amRNSBleepa® achieves CE Mark
21st May 20207:00 amRNSPapworth NHS Hosp - contract renewal with Bleepa
29th Apr 20202:05 pmRNSSecond Price Monitoring Extn
29th Apr 20202:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.